Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy LabCorp (LH) Stock?

The SARS-CoV-2 Research Sequencing Panel will help LabCorp (LH) sequence thousands of complete coronavirus genomes each week from positive patient samples.

LabCorp (LH), Molecular Loop Team Up for COVID-19 Test Research

NEWTON, Mass., June 22, 2021 /PRNewswire/ -- Molecular Loop Biosciences, Inc. , a company redefining the simplicity of targeted sequencing, announced today that its SARS-CoV-2 Research Sequencing Panel has been deployed by Labcorp (NYSE: LH), a leading global life sciences company, to help sequence thousands of complete coronavirus genomes each week from positive patient samples.

Labcorp Adopts Molecular Loop SARS-CoV-2 Research Sequencing Panel for Large-Scale Viral Surveillance

Quest Diagnostics

These companies dominate a vital medical industry niche, and their valuations are near their all-time lows.

2 Incredibly Cheap Healthcare Stocks

LabCorp (LH) enables evidence-based, personalized treatment suggestions based on the genomic profiling of a patient's solid tumor with the launch of new test.

LabCorp (LH) Boosts Precision Oncology With INSIGHT NGS Launch

BUFFALO, N.Y., June 14, 2021 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, and OmniSeq, a CAP-accredited, molecular diagnostic innovation of Roswell Park Comprehensive Cancer Center, today announced the launch of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling, tissue-based test that integrates next-generation sequencing (NGS) technology.

Labcorp And OmniSeq Launch INSIGHT℠, Next-Generation Sequencing Platform to Advance Precision Oncology

Apollo Medical Hlds

Fulgent Genetics

HCA Healthcare

Joint

Surgery Partners

Tenet Healthcare

These seven healthcare stocks are in a good position to take off as baby boomers continue to age into retirement. The post 7 Healthcare Stocks to Buy for Changing Demographics appeared first on InvestorPlace.

7 Healthcare Stocks to Buy for Changing Demographics

According to LabCorp (LH), the on-demand delivery option is useful for individuals showing symptoms of COVID-19 infection who want to be tested without potentially infecting others.

LabCorp's (LH) Pixel Home Collection Kit Now in WBA Stores

BURLINGTON, N.C. & DEERFIELD, Ill.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company today announced that Pixel by Labcorp® COVID-19 PCR Test Home Collection Kits are now in 6,000 Walgreens stores nationwide and through Walgreens collaborations with on-demand delivery services DoorDash and Instacart. The newly expanded availability and delivery option advances Walgreens and Labcorp's efforts to increase COVID-19 testing access in communities across the U.S., especiall

Pixel by Labcorp® COVID-19 PCR Test Home Collection Kits Now Available Nationwide at Walgreens and Through On-Demand Delivery

AutoZone

Copart

VeriSign

According to the GuruFocus All-in-One Screener, a Premium feature, the following companies have high business predictability ratings and wide margins of safety as of June 8.

5 Predictable Stocks Gurus Are Buying

Thermo Fisher Scientific

MedTech testing stocks like Quest Diagnostics Incorporated (DGX), Thermo Fisher Scientific, Inc. (TMO) and Laboratory Corporation of America Holdings (LH) are likely to survive post-pandemic.

3 Medical Diagnostics Stocks in Focus on Long-Term Potential

W. R. Grace & Co.

Investors Bancorp

Ruth's Hospitality Group

Michael Price (Trades, Portfolio)'s MFP Investors LLC recently disclosed its portfolio updates for the first quarter of 2021, which ended on March 21.

Michael Price's Top 1st-Quarter Trades

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the introduction of its combined Labcorp oncology platform at the virtual 2021 American Society of Clinical Oncology (ASCO®) Annual Meeting held June 4-8. Labcorp's oncology platform brings together the company's leadership in diagnostic testing with its comprehensive drug development services, delivering targeted solutions for oncology by leveraging breakthrough science and insights f

Labcorp to Introduce Combined Oncology Offering at 2021 ASCO® Annual Meeting

LabCorp (LH) claims this to be the largest known COVID-related study in terms of specimen volume.

LabCorp (LH) New Study Looks at COVID-19 Antibody Longevity

Like many other diagnostics and drug development companies, Laboratory Corp. of America Holdings ( LH , Financial) saw its base business decline as Covid-19 took hold. Fewer patients sought routine medical care and many clinical trials were suspended, leading to a decline in its two streams of revenue.

Laboratory Corp: A Solid Margin of Safety

BURLINGTON, N.C.--(BUSINESS WIRE)--Nearly 87% of naturally infected COVID-19 patients maintained antibodies to SARS-CoV-2 proteins for at least 10 months, according to a new Labcorp (NYSE: LH) analysis of specimens from 39,086 individuals. The study, published May 24 in The Lancet-affiliated EClinicalMedicine, offers real-world evidence of the body's response to the virus and the possibility of protection against future infection. It is the largest known COVID-19-related study by specimen volum

Labcorp Study Suggests COVID-19 Antibodies Remain at Least 10 Months After Infection

Bloomin' Brands

Encompass Health

Perspecta Inc

TreeHouse Foods

Jana Partners (Trades, Portfolio), a New York-based investment firm, disclosed this week that its top five trades during the first quarter included the reduction in its holdings in Perspecta Inc. ( PRSP , Financial) and Encompass Health Corp. ( EHC , Financial), the closure of its position in Bloomin Brands Inc. ( BLMN , Financial) and boosts to its stakes in Treehouse Foods Inc. ( THS , Financial) and Laboratory Corp of America Holdings ( LH , Financial).

Jana Partners' Top 5 Trades in the 1st Quarter

Bunge Global SA

Leju Holdings Ltd.

If seeking for high return investments amid non-cyclical stocks, investors could be interested in the three companies listed below, as their earnings yields (as calculated via Joel Greenblatt ( Joel Greenblatt , Portfolio)'s method) are outperforming the U.S. market.

A Trio of High Return Non-Cyclical Stocks for the Value Investor

The new laboratory by LabCorp (LH) is set to enable faster data turnaround for early phase trials in Asia-Pacific markets.

LabCorp's (LH) New Bioanalytical Lab to Boost APAC Operation

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the expansion of its drug development offering in the Asia-Pacific region with the addition of bioanalytical services in Singapore. “Singapore is a crucial region for strengthening Labcorp's extensive global presence, offering our clients—both in-region and international—a complementary site to support their bioanalytical studies,” said Stephane Sidobre, vice president and head of Labc

Labcorp to Expand Bioanalytical Services With Integrated Laboratory in Singapore

LabCorp (LH) becomes the first major commercial laboratory to offer a COVID-19 PCR Test Home Collection Kit for children and adolescents.

LabCorp's (LH) Pixel Kit Gets EUA for Younger Population

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at the UBS Global Healthcare Virtual Conference on Monday, May 24 at 3:00 p.m. ET. A live webcast of the presentation will be available via the Investor Relations section of the company's website at www.Labcorp.com and archived for replay. About Labcorp Labcorp is a leading global life sciences co

Labcorp to Speak at UBS Global Healthcare Virtual Conference

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Pixel by Labcorp COVID-19 PCR Test Home Collection Kit for ages 2-17. The authorization expands the use of Pixel by Labcorp to children and adolescents 2 years of age and older when purchased by a parent or guardian. “Expanding access of our Pixel by Labcorp COVID-19 Test Home Collect

Pixel by Labcorp COVID-19 PCR Test Home Collection Kit Receives FDA Emergency Authorization for Ages 2-17

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH) (“Labcorp”) announced today that it has priced its offering of $1,000,000,000 in senior notes. The offering consists of two tranches: $500,000,000 aggregate principal amount of 1.550% Senior Notes due 2026 (the “2026 Notes”) and $500,000,000 aggregate principal amount of 2.700% Senior Notes due 2031 (the “2031 Notes” and, together with the 2026 Notes, the “Notes”). The Notes will bear interest from May 26, 2021, payable semi-annually on June

Labcorp Prices $500,000,000 in 1.550% Senior Notes Due 2026 and $500,000,000 in 2.700% Senior Notes Due 2031

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH) (“Labcorp”) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in two tranches (the “Notes”). The Notes will be senior unsecured obligations and will rank equally with Labcorp's existing and future senior unsecured debt. Labcorp expects to use the net proceeds of the Notes offering to redeem, prior to maturity, its outstanding 3.20% Senior Notes due Feb. 1, 2022 and 3.7

News for Labcorp Holdings Inc Stock (LH)